Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Hydroxyurea
Drug ID BADD_D01110
Description An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Indications and Usage For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.
Marketing Status approved
ATC Code L01XX05
DrugBank ID DB01005
KEGG ID D00341
MeSH ID D006918
PubChem ID 3657
TTD Drug ID D07CWD
NDC Product Code 0904-6939; 35369-0006; 49452-3650; 55154-7143; 61269-403; 68084-284; 70518-3615; 51927-0072; 0555-0882; 55154-3554; 69315-164; 38779-1354; 42291-321; 71770-105; 49884-724; 17337-0023; 0003-6335; 0003-6337; 60429-265; 61269-835; 70518-0916; 55512-0003; 61269-402; 71770-120; 0003-0830; 51552-0851; 62049-135; 0003-6336; 61269-404; 10135-702; 71052-323; 17337-0022
UNII X6Q56QN5QC
Synonyms Hydroxyurea | Hydroxycarbamid | Oncocarbide | Hydrea
Chemical Information
Molecular Formula CH4N2O2
CAS Registry Number 127-07-1
SMILES C(=O)(N)NO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hernia08.01.04.0010.000280%Not Available
Hyperglycaemia14.06.02.002; 05.06.02.0020.000168%
Hyperkalaemia14.05.03.0010.000448%
Hyperkeratosis23.01.01.0010.000112%
Hypersensitivity10.01.03.003--
Hypersensitivity vasculitis24.12.04.013; 23.06.02.005; 10.02.02.017; 01.01.04.0080.000168%Not Available
Hypersplenism01.09.02.0020.000168%Not Available
Hyperuricaemia14.09.01.0030.000224%
Hypocalcaemia14.04.01.0040.000112%
Hypoglycaemia14.06.03.001; 05.06.03.0010.000358%
Hypomagnesaemia14.04.02.001--
Hyponatraemia14.05.04.0020.000280%
Hypoxia22.02.02.0030.000168%
Ileal ulcer07.04.06.0080.000112%
Ileus07.13.01.0010.000112%
Impaired healing08.03.02.0010.000358%Not Available
Increased tendency to bruise24.07.06.012; 23.06.01.009; 01.01.03.0050.000112%Not Available
Infection11.01.08.002--Not Available
Inguinal hernia07.16.02.0010.000168%Not Available
Interstitial lung disease22.01.02.003; 10.02.01.0330.001959%Not Available
Intestinal obstruction07.13.01.0020.000112%Not Available
Iron deficiency anaemia14.13.02.001; 01.03.01.0020.000112%Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Large intestinal ulcer07.04.06.0040.000112%
Laryngeal cancer22.08.02.001; 16.19.03.0010.000112%Not Available
Leukaemia16.01.03.001; 01.10.03.0010.000336%
Leukocytosis01.02.01.0020.000783%
Leukopenia01.02.02.0010.000224%Not Available
Liver disorder09.01.08.0010.000504%Not Available
Lung disorder22.02.07.0010.000168%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene